Form 990 for tax year 2023

Totals

Total revenue

$6,346,368

Total expenses

$6,504,180

Contributions and grants received

$6,213,200

Grants paid

$1,293,517

Program service revenue

$10,876

Investment income

$122,292

Other revenue

$0

Total assets, end of year

$10,423,827

Total liabilities, end of year

$3,872,730

Net assets or fund balances, end of year

$6,551,097

Program services expenses (Part IX)

$5,618,099

Management and general expenses

$825,980

Fundraising expenses

$60,101

Program service expenses (Part III)

$5,618,099

Program services were 86.4% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2023

• EMERGING SYSTEMS TOXICOLOGY FOR THE ASSESSMENT OF RISK (ESTAR): THE MISSION OF THIS COMMITTEE IS TO DEVELOP AND DELIVER INNOVATIVE SYSTEMS TOXICOLOGY APPROACHES FOR RISK ASSESSMENT. THIS INCLUDES THE CATALYZE ADOPTION OF NEW TRANSLATIONAL AND PREDICTIVE TOOLS THAT GUIDE DECISION-MAKING BASED ON MECHANISTIC UNDERSTANDING OF TOXICOLOGICAL RESPONSE, ENGAGING THE GLOBAL SCIENTIFIC COMMUNITY TO PROMOTE INTERNATIONAL ACCEPTANCE OF GENOMIC BIOMARKERS FOR DECISION-MAKING, AND IDENTIFYING AND CHARACTERIZING BIOFLUID AND TISSUE-BASED GENOMIC BIOMARKERS FOR TOXICOLOGY. THE COMMITTEE HAS SIX ACTIVE PROJECTS, INCLUDING THE OMICS FOR ASSESSING SIGNATURES FOR INTEGRATED SAFETY (OASIS) CONSORTIUM, WHICH IS INVESTIGATING THE USE OF CELL PAINTING AND TRANSCRIPTOMICS FROM IN VITRO MODELS AND COMPARING THEM TO EXISTING RAT IN VIVO DATA. ANOTHER PROJECT IS EVALUATING THE USE OF ERROR CORRECTED SEQUENCING TO DETECT CLONAL EXPANSION INDUCED BY NON-GENOTOXIC CARCINOGENS. EXISTING PROJECTS HAVE MADE GREAT PROGRESS AS WELL IN 2023. THE TGX-DDI PROJECT WAS AWARDED A U01 GRANT FROM THE US FDA'S BIOMARKER QUALIFICATION PROGRAM, WHICH ALLOWED IT TO COMPLETE A MULTI-SITE TRIAL FOR QUALIFICATION. THE COMMITTEE HAS PUBLISHED TWO MANUSCRIPTS THIS YEAR AND HAS PRESENTED AT 4 SCIENTIFIC MEETINGS.

  Expenses $910,718 · Grants $652,838

• CARDIAC SAFETY TECHNICAL COMMITTEE: THE MISSION OF THE CARDIAC SAFETY TECHNICAL COMMITTEE IS TO IMPROVE PUBLIC HEALTH BY REDUCING UNANTICIPATED CARDIOVASCULAR-RELATED ADVERSE EFFECTS FROM DRUGS OR CHEMICALS AND DEVELOP INNOVATIVE APPROACHES TO SUPPORT EARLY DETECTION AND PREDICTION AS WELL AS IMPROVED UNDERSTANDING OF CARDIOVASCULAR TOXICOLOGY AND PATHOBIOLOGY. IN 2023, THE COMMITTEE CONTINUED TO SPONSOR PROJECTS ADDRESSING CARDIOVASCULAR SAFETY TESTING, PUBLISHED TWO SCIENTIFIC MANUSCRIPTS IN A PEER-REVIEWED TECHNICAL JOURNAL BASED ON THE COMMITTEE'S RESEARCH AND PRESENTED 9 TIMES AT PUBLIC SCIENTIFIC MEETINGS. AN ADDITIONAL 6 MANUSCRIPTS ARE IN PROGRESS. KEY PROJECTS INCLUDED CONTINUATION OF A NEW STUDY TO EXPLORE DRUG-INDUCED BLOOD PRESSURE CHANGES, A STUDY TO IDENTIFY BIOMARKERS OF BLEEDING DISORDERS, PROJECT PLANNING TO EXPLORE CARDIAC FUNCTION AND SODIUM CHANNEL BLOCK, AND COMPLETION OF DATA ANALYSIS FOR A NEW STUDY TO EXPLORE USE OF CARDIAC STEM CELLS TO PREDICT TOXICITY. THE COMMITTEE ALSO CONTINUED THEIR SUPPORT OF TWO GRANTS AWARDED THROUGH FDA AND NIH IN SUPPORT OF A STRATEGIC FRAMEWORK TO ENHANCE THE USE OF MECHANISTIC STUDIES TO PREDICT POTENTIAL CARDIAC RISKS FOR PHARMACEUTICALS. THE GRANTS INCLUDE SUBCONTRACTS AT SEVERAL LABORATORIES IN THE US AND EUROPE.

  Expenses $901,354 · Grants $277,441 · Revenue $1,701

• BOTANICAL SAFETY CONSORTIUM (BSC): THE BSC WAS OFFICIALLY CONVENED IN NOVEMBER 2019, AS THE RESULT OF A MEMORANDUM OF UNDERSTANDING BETWEEN THE US FDA, THE NATIONAL INSTITUTES OF HEALTH'S NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES (NIEHS), AND THE NON-PROFIT HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE (HESI). THE CONSORTIUM IS SUPPORTED VIA US FEDERAL FUNDING AND PRIVATE SECTOR CONTRIBUTIONS TO CREATE A PARTNERSHIP TO ADVANCE THE SCIENCE OF BOTANICAL EVALUATION. WITH THE ENGAGEMENT OF A BROAD GROUP OF GLOBAL STAKEHOLDERS, THE BSC'S MISSION IS TO ESTABLISH SUITABLE LEVELS OF CHEMICAL CHARACTERIZATION FOR BOTANICALS AND IDENTIFY FIT-FOR-PURPOSE IN VITRO AND IN SILICO ASSAYS THAT CAN BE USED TO EVALUATE BOTANICAL SAFETY. THE BSC IS COMPRISED OF EXPERTS IN AREAS RELATED TO PHARMACOGNOSY, NATURAL PRODUCTS CHEMISTRY, MODELING, TOXICOLOGY, AND/OR NEW APPROACH METHODOLOGIES. AN UP-TO-DATE LIST OF PARTICIPATING ORGANIZATIONS CAN BE FOUND AT WWW.BOTANICALSAFETYCONSORTIUM.ORG. PRIORITIZED TOXICITY ENDPOINTS LED TO THE FORMATION OF SIX ENDPOINT WORKING GROUPS: HEPATOTOXICITY, CARDIOTOXICITY, NEUROTOXICITY, GENOTOXICITY, DEVELOPMENTAL AND REPRODUCTIVE TOXICITY (DART), AND SYSTEMIC TOXICITY. THERE IS ALSO CONSIDERABLE FOCUS ON EVALUATION OF ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION (ADME) AND BOTANICAL-DRUG INTERACTIONS (BDIS) WITHIN THESE WORKING GROUPS. ALL TOXICOLOGICAL ENDPOINT GROUPS WORK IN COLLABORATION WITH THE CHEMICAL AND DATA ANALYSIS GROUPS FOR SUBSTANCE CHARACTERIZATION, EXPERIMENTAL DESIGN, AND ULTIMATELY, EVALUATION OF RESULTS. IN VITRO TO IN VIVO EXTRAPOLATION (IVIVE) IS A KEY CONSIDERATION FOR THE VARIOUS ENDPOINTS AND ASSAYS TO ENSURE THAT THE RESULTS FROM THE ASSAYS CAN BE APPROPRIATELY COMPARED TO AVAILABLE ANIMAL AND HUMAN SAFETY INFORMATION. IN 2023, THE BSC MADE PRESENTATIONS AT VARIOUS SCIENTIFIC MEETINGS INCLUDING THE SOCIETY OF TOXICOLOGY ANNUAL MEETING AND THE INTERNATIONAL CONGRESS OF NATURAL PRODUCTS RESEARCH.

  Expenses $380,158

• ECO RISK; IN VITRO GENOTOXICITY; NITROSAMINE GRANT; DEV AND REPRODUCTIVE TOX; CT TRACS; PROTEIN ALLERGENICITY; IMMUNOTOXICOLOGY; ANNUAL MEETING; THRIVE; COMMUNICATIONS AND OUTREACH; PROTAC; UVCB; ACSA 2; EMERGING ISSUES CMTE; CORA OTOTOXICITY; ENV EPI RA; PB/PK; GRATC; RA 21ST CENTURY; NEOUROTOX BIOMARKERS; FAST FUND; EXTERNAL ADVISORY; PROG STRATEGY AND STEWARDSHIP; BIOACCUMULATION; ADC; HESI HELPS.

  Expenses $3,425,869 · Grants $363,238 · Revenue $9,175

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

• BROAD INSTITUTE

  $546,000

  RESEARCH SUPPORT

• STANFORD UNIVERSITY

  $274,941

  RESEARCH GRANT

• GEORGETOWN UNIVERSITY

  $106,088

  RESEARCH GRANT

• NATIONAL SCIENCE TEACHING ASSOCIATION

  $70,000

  RESEARCH GRANT

• UNIVERSITY OF COLORADO DENVER - SKAGGS SCHOOL OF PHARMACY AND PHARMACEUTICA

  $37,750

  THRIVE RESEARCH GRANT

• BETH ISRAEL DEACONESS MEDICAL CENTER INC

  $37,750

  THRIVE RESEARCH GRANT

• RUTGERS THE STATE UNIVERSITY OF NEW JERSEY

  $37,750

  THRIVE RESEARCH GRANT

• UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

  $27,500

  THRIVE RESEARCH GRANT

• MIDDLE TENNESSEE STATE UNIVERSITY

  $20,000

  RESEARCH GRANT

• TERATOLOGY SOCIETY

  $15,000

  ANNUAL MEETING SPONSOR

The 10 largest by cash amount. The API serves every itemized grant.

Provenance

Return type

form_990

Tax year

2023

Filed

29 October 2024

IRS schema version

2023v5.1

Source object

202433039349301228

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.